

INTERNET ARCHIVE  
**WayBackMachine**

41 captures  
1 Jul 01 - 21 Jan 13

JUN JUL AUG  
2000 2001 2002

## PERIPHERAL & CENTRAL NERVOUS SYSTEM DRUGS ADVISORY COMMITTEE

June 6, 2001

### Briefing Information

Consideration of NDA 21-196, Xyrem (sodium oxybate, Orphan Medical Inc.), proposed to reduce the incidence of cataplexy and to improve the symptom of daytime sleepiness for persons with narcolepsy.

### Orphan Medical Presentations

#### *Disclaimer*

The statements contained in this document are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

### Briefing Information [pdf](#)

Xyrem Prescription and Distribution Process, *Video Script 2/2/01*) [html](#) [pdf](#)

### [Video](#)

### FDA Briefing Information

Index [pdf](#)

Overview Memo [pdf](#)

Efficacy Review [pdf](#)

Safety Review [pdf](#)

Major Amendment Review [pdf](#)

Controlled Substance Overview [pdf](#)